<DOC>
	<DOCNO>NCT00714883</DOCNO>
	<brief_summary>The primary objective study evaluate target lesion failure rate NEVO Sirolimus-eluting Coronary Stent System .</brief_summary>
	<brief_title>Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution Native Coronary Artery Lesions</brief_title>
	<detailed_description />
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subjects atherosclerotic CAD ; The subject must &gt; /= 18 year age ; Female childbearing potential must negative pregnancy test within 7 day prior enrollment ; Diagnosis angina pectoris define stable angina pectoris Canadian Cardiovascular Society Classification ( Class I , II , III ) OR nonST segment elevation acute coronary syndrome ( Braunwald Classification B &amp; C ) OR OR nonST segment elevation myocardial infarction â‰¥ 48 hour time study index procedure OR asymptomatic subject positive stress test ; Indicated treatment two lesion one two major coronary artery ( 1 target lesion 2 vessel 2 target lesion 1 vessel ) . The target vessel diameter must &gt; /= 2.25mm &lt; /= 3.5 diameter ( visual estimate ) ; Target lesion length &lt; /= 28 mm able treat single stent . If require , additional Conor Sirolimus stent use treat dissection , etc Patient Legally Authorized Representative must provide write informed consent prior procedure use form approve Independent Ethics Committee . The patient willing comply specify followup evaluation . The target lesion successfully cross intracoronary guidewire position intraluminally distal vessel . The target lesion diameter stenosis &gt; 50 % &lt; 100 % base visual estimate . STelevation MI within 72 hour prior index procedure and/or creatine kinase ( CK ) &gt; 2 time local laboratory upper limit normal day index procedure . The patient undergone target vessel revascularization within 6 month prior intend enrolment procedure . Prior stent within 5 mm target lesion ( ) ; Ostial target lesion ( ) ; Unprotected leave main coronary disease &gt; /= 50 % stenosis ; Angiographic evidence thrombus within target lesion ( ) ; Total coronary occlusion TIMI grade 0 1 target vessel ; Bifurcation disease involve side branch &gt; /= 2 mm diameter ; Target lesion ( ) within coronary bypass graft ( e.g. , saphenous vein arterial graft ) ; Significant calcification angulation target vessel , Investigator 's opinion , may preclude stent delivery deployment ; Recipient heart transplant ; Subject life expectancy le 12 month ; Known allergy follow : aspirin , thienopyridine , heparin , cobalt chromium , contrast agent ( manage medically ) , sirolimus manage medically ; The patient contraindication ASA thienopyridine agent . Currently participate investigational drug device study complete primary endpoint clinically interfere study endpoint ; Known bleed hypercoagulable disorder ; Known suspect active infection time study procedure ; Subject known prisoner , mentally incompetent , and/or alcohol drug abuser ; Subject major surgical interventional procedure unrelated study within 30 day prior study planned surgical interventional procedure within 30 day entry study , plan coronary PCI end study . The patient currently take systemic immunosuppressant therapy ; The patient comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>Percutaneous coronary intervention ( PCI )</keyword>
</DOC>